Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

Aslan Pharmaceuticals Ltd ASLN

• On July 17, ASLAN Pharmaceuticals announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. The company said this decision was made following a thorough review of ASLAN SG's financial situation and strategic options. The company's stock fell around 69% over the past five days and has a 52-week low of $0.48.
• RSI Value: 25.34
• ASLN Price Action: Shares of Aslan Pharmaceuticals fell 37% to close at $0.70 on Wednesday.
• Benzinga Pro's real-time newsfeed alerted to latest Aslan Pharmaceuticals news.

CERo Therapeutics Holdings Inc CERO    

• On June 13, the company executed pre-IND manufacturing activities for its lead therapeutic, CER-1236. The company's stock fell around 33% over the past month. It has a 52-week low of $0.16.
• RSI Value: 20.79
• CERO Price Action: Shares of CERo Therapeutics gained 6.2% to close at $0.21 on Wednesday.
• Benzinga Pro's charting tool helped identify the trend in CERO stock.

Organovo Holdings Inc ONVO

• On July 16, Organovo presented the company’s outlook and plans at Jones Trading Healthcare Conference. The company's stock dipped around 18% over the past five days and has a 52-week low of $0.55.
• RSI Value: 20.53
• ONVO Price Action: Shares of Organovo fell 5.2% to close at $0.59 on Wednesday.
• Benzinga Pro's signals feature notified of a potential breakout in Organovo shares.

Read Next:

• Jim Cramer Says Don’t Sell Match Group: ‘You’ve Just Got A Very, Very Smart Investor In There‘